Truist raised the firm’s price target on AbbVie (ABBV) to $217 from $211 and keeps a Buy rating on the shares after its Q4 results. The company’s FY24 results exceeded the management’s recent guidance as AbbVie continues to deliver strong growth into the longer-term, and the firm sees a clear growth trajectory into 2029, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: